ArticleBMC chemistry2026
An analytical framework for nanohydroxyapatite evaluation by ICP-OES and quantification of hydroxyapatite-equivalent Ca and P in toothpaste formulations through multivariate optimization.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nano-hydroxyapatite (nHA) is widely incorporated into toothpaste as a biomimetic agent for preventive oral care, yet robust quantitative methods for determining its content in finished formulations remain limited. In this study, nHA was first characterized structurally and morphologically to establish a reference material. X-ray diffraction (XRD) confirmed high crystallinity consistent with pure hydroxyapatite. High-resolution transmission electron microscopy (HRTEM) revealed rod-shaped nanoparticles with an average size of 22.36 nm and an aspect ratio of 2.25. Fourier transform infrared spectroscopy (FTIR) further verified characteristic phosphate vibrational bands at 1023.25, 562.26, and 600.84 cm⁻¹. Following characterization, nHA was incorporated into a toothpaste formulation, and an analytical strategy was developed to quantify hydroxyapatite-equivalent content based on stoichiometric determination of calcium (Ca) and phosphorus (P) using inductively coupled plasma optical emission spectroscopy (ICP-OES). A 2³ factorial design was employed to optimize key instrumental parameters-nebulization gas flow rate, applied power, and plasma flow rate. Exploratory statistical tools, including ANOVA, Pareto charts and residual analyses, identified nebulization gas flow rate as the most influential factor. The optimized method was validated for linearity, sensitivity, accuracy, precision, robustness and matrix interference. Calibration curves for both standard and matrix-matched solutions showed excellent linearity (R² > 0.999). Limits of quantification were 25.16 µg L⁻¹ for Ca and 12.24 µg L⁻¹ for P. Spike recoveries ranged from 95% to 110%, confirming method accuracy. Because ICP-OES measures total elemental Ca and P after digestion, the method quantifies hydroxyapatite-equivalent content and does not distinguish nHA from other Ca/P-containing ingredients. Nonetheless, application to commercial toothpaste samples yielded results consistent with label claims, demonstrating the method's suitability for quality control of hydroxyapatite-containing formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.